Articles

• New Scientific Committee members announced
• Catalysing new thinking on the development of cancer
• OPTIMISTICC: New connection drives poor outcomes in bowel cancer
• Metabolic fingerprinting reveals link between dietary fat restriction and therapy response
• Nature Reviews Drug Discovery: addressing cancer’s grand challenges
• The power of discovery: 7 teams leading the way
• The Challenges: Professor Sir David Lane shares his thoughts on the macromolecules challenge
• AACR Cancer Discovery: Cancer Grand Challenges to fund broad, pressing research
• AACR Cancer Discovery In Focus: embarking on a new era of discovery
• The Challenges: Professor Crystal Mackall on the solid tumours in children challenge
• The Challenges: Professor René Bernards on the senescence challenge
• STORMing Cancer's Professor Don Ingber receives prestigious Wilbur Cross Medal
• The Challenges: Professor Karen Vousden on the normal phenotypes challenge
• Multidisciplinary collaboration driving new discoveries: uncovering the role of SLC7A5 in KRAS-driven colorectal cancer
• Pre-application webinar: everything you need to know about applying
• The Challenges: Professor Nic Jones on dormancy
• The Challenges: Ed Harlow shares his thoughts on the inflammation challenge
• News from the IMAXT team: Expansion Sequencing technology
• The Challenges: Professor Charlie Swanton discusses the cachexia challenge
• “We wanted to do everything we could to support them”: Nick and Annette Razey give £1m to back Cancer Grand Challenges team
• The Challenges: Professor Charlie Swanton discusses the extrachromosomal DNA challenge
• Professor Barbara Rimer on aspiring to create an inclusive world #IWD2021
• Michele Cleary on celebrating women in science #IWD2021
• Challenging the status quo and collaborating across disciplines in the IMAXT team #IWD2021
• The value of good mentorship: Amy Schade and Karen Cichowski celebrate #IWD2021
• Kimmie Ng and Candace Henley celebrate the value of the patient advocacy voice in cancer research #IWD2021
• Could the size of fat cells around DCIS breast lesions predict risk of future invasive cancer?
• The Challenges: Professor David Hunter shares his thoughts on e-cigarettes
• The microbiome: a biomarker for colorectal cancer?
• In conversation with Owen Sansom and Helen Matthews, SPECIFICANCER
• AACR Meet the Experts Session
• Inside Project Theia, the world’s first virtual reality cancer research lab – and a call for volunteers
• 7 Questions with... Jelle Wesseling, PRECISION
• Caitlin Brennan discusses the microbiome and aspirin's potential in personalised prevention
• Survival of the fittest: revealing the early stages of APC-driven colorectal cancer
• Announcing the shortlist for the Cancer Grand Challenges awards
• Questions with...Johanna Joyce, IMAXT
• Questions with...Mike Stratton, Mutographs
• A COSMIC catalogue of cancer data, with Mutographs' Ellie Dunstone
• IMAXT’s Nic Walton: uniting across disciplines to share learnings in data science
• Cindy Sears: the power of preclinical models and learnings from global health
• 7 Questions with... John Marioni, IMAXT
• Discover: a year of scientific creativity
• New findings, old ideas: reviving a decades old view on the causes of cancer
• Unravelling the drivers of immune evasion in head and neck cancer
• Escape from the immune system
• New thinking on the process of ageing
• A step closer to distinguishing harmless from invasive breast lesions 
• Hidden treasure: do the clues to preventing and detecting colorectal cancer lie in the microbiome?
• Matrix remodelling in the transformation from inflammation to malignancy   
• Uncharted territory: metabolic tumour maps reveal new therapeutic avenues
• Genes in space: the future of biology is spatial
• The rules (not the exceptions) of cancer tissue specificity
• “We can all be agents of change” - learnings from our first Future Leaders Conference
• Unravelling the mystery of oesophageal cancer incidence, by Mutographs’ Sarah Moody
• Unexpected findings from the Mutographs team: huge global variation in oesophageal cancer incidence is not due to a unique pattern of DNA damage
• Why virtual reality is the future
• Cancer Revolution: Science, Innovation and Hope – a world-first exhibition
• Spotlight: our work in pancreatic cancer
• Bjorn Saven: why developing the infrastructure for early career researchers to thrive will bring about meaningful change